Amphiphilic block copolymer micelles for nanoscale drug delivery
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Amphiphilic block copolymers can assemble into supramolecular core‐shell structures, termed ABC micelles, that have proven utility in drug delivery, particularly for drug solubilization. Several examples have entered clinical trials, attesting to the biocompatibility of ABCs and the potential advantages for drug delivery, e.g., low toxicity relative to Cremophor® EL, a surfactant commonly used for drug solubilization. Several examples of ABC micelles demonstrate potential for prolonged circulation in blood. Coupled with novel strategies toward controlled release of drug, nanoscale ABC micelles have tremendous potential for the targeting of antitumor agents, many of which are poorly water soluble and possess dose‐limiting toxicity. Drug Dev. Res. 67:15–22, 2006. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · cited 1×
“Efforts on ABC micelles build on findings established firmly in research on polymer therapeutics, e.g., water-soluble polymer-drug conjugates, and longcirculating liposomes [Allen and Cullis, 2004], and these have entered clinical trials and have had a positive clinical impact in cancer therapy.”
BackgroundPluronic® block copolymers as novel polymer therapeutics for drug and gene delivery
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00009-3 · Cited by 1,474
Bae, Y., Fukushima, S., Harada, A., & Kataoka, K. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200250653 · Cited by 1,329
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734 · cited 2×
“The maximum tolerated dose of Taxol in nude mice is approximately 20 mg/kg, whereas the maximum tolerated dose of paclitaxel in PEO-b-PLA micelles is approximately 60 mg/kg [Kim et al., 2001].”
BackgroundPhase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · cited 1×
“Thus, PEO-b-PAsp-DOX micelles are being evaluated in Phase II clinical trials at the National Cancer Institute in Japan with an emphasis on pancreatic cancer [Matsumura et al., 2004].”
BackgroundPolymeric Micelles for Delivery of Poorly Water-Soluble Compounds
Kwon, G. S. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i5.20 · Cited by 502
Self-citationLiu, J., Xiao, Y., & Allen, C. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10533 · Cited by 358 · cited 1×
“Coupled with greater theoretical insight, we can expect better predictions of compatibility between a poorly water-soluble drug and core-forming block for efforts in drug solubilization with ABC micelles [Liu et al., 2004].”
BackgroundLiggins, R. T., & Burt, H. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00016-9 · Cited by 286 · cited 1×
“…of poly (ethylene oxide) (PEO), a non-toxic water-soluble polymer and a hydrophobic block, which is poly (propylene oxide) (PPO), poly-(L-amino acid), or a poly(ester), e.g., poly(lactic acid) (PLA), a well-known biodegradable and biocompatible polymer in drug delivery [Liggins and Burt, 2002].”
Background
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Polymeric micelles as drug delivery vehicles
Ahmad, Z., Shah, A., Siddiq, M., & Kraatz, H.-B. (2014) · RSC Adv. · doi:10.1039/c3ra47370h · Cited by 610
Poly(2-oxazolines) in biological and biomedical application contexts
Adams, N., & Schubert, U. S. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.018 · Cited by 492
Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery
Xiong, X.-B., Falamarzian, A., Garg, S. M., & Lavasanifar, A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.04.028 · Cited by 268
pH and Reduction Dual-Sensitive Copolymeric Micelles for Intracellular Doxorubicin Delivery
Chen, J., Qiu, X., Ouyang, J., Kong, J., Zhong, W., & Xing, M. M. Q. (2011) · Biomacromolecules · doi:10.1021/bm200804j · Cited by 259
Metadata
- Authors
- Kwon, G. S., & Forrest, M. L.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 67
- Issue
- 1
- Pages
- 15-22
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2023629284
- Cited by
- 148
- References
- 9
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.